Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30257103 | 1.00 | NSD2 (0.31) | NSD2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL25555318 | 0.93 | NSD2 (0.34) | NSD2 | |
| SCHEMBL25554977 | 0.93 | NSD2 (0.33) | NSD2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL25058400 | 0.90 | CYP19A1 (0.31) | NSD2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL25058120 | 0.88 | PDE10A (0.30) | — | |
| SCHEMBL25555151 | 0.88 | CYP19A1 (0.32) | NSD2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL25058579 | 0.87 | CYP19A1 (0.32) | NSD2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL25555177 | 0.87 | NSD2 (0.33) | NSD2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL28989314 | 0.87 | GAA (0.33) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL25555260 | 0.87 | NSD2 (0.32) | NSD2CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115996910-A | Aryl or heteroaryl derivatives | 帝人制药株式会社 | 2023-04-21 | — | — | CN | claimed |
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
| CN-115996910-A | Aryl or heteroaryl derivatives | 帝人制药株式会社 | 2023-04-21 | — | — | CN | disclosed |
| EP-4137481-A1 | ARYL OR HETEROARYL DERIVATIVE | Teijin Pharma Limited (JP) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021210650-A1 | ARYL OR HETEROARYL DERIVATIVE | 帝人ファーマ株式会社 | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | ARRB1, NR3C2, TRPC6 | NSD2 3265/4885CYP19A1 3966/4885CYP11B1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.